Medicare Part D coverage · mesalamine · RxCUI 580286
mesalamine 500 MG Extended Release Oral Capsule [Pentasa]
Per the CMS 2026 Part D formulary file, mesalamine 500 MG Extended Release Oral Capsule [Pentasa] is covered by 896 Medicare Part D plans (17.7% of enrollable products), averaging Tier 3.4, with prior authorization required on 0% of covering formularies.
- 17.7%
- Plan coverage
- 896
- Plans covering
- T3.4
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for mesalamine 500 MG Extended Release Oral Capsule [Pentasa]
Per the CMS 2026 Part D formulary file, mesalamine 500 MG Extended Release Oral Capsule [Pentasa] (RxNorm concept RXCUI 580286, generic name mesalamine) appears on 8 distinct formulary files spanning 896 Medicare Part D plan offerings - 17.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.4.
Real-world access to mesalamine 500 MG Extended Release Oral Capsule [Pentasa] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 62.5% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 95,185 Part D beneficiaries filled mesalamine 500 MG Extended Release Oral Capsule [Pentasa] in 2023, with total plan-and-beneficiary spending of $271,494,414 and an average per-beneficiary annual cost of $2,852.28. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry mesalamine 500 MG Extended Release Oral Capsule [Pentasa] today.
Coverage Details
- Formularies covering
- 8
- Plans covering
- 896
- Coverage rate
- 17.7%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 62.5% of formularies
2023 Medicare Spending
- Beneficiaries
- 95,185
- Total spending
- $271,494,414
- Avg per beneficiary
- $2,852.28
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering mesalamine 500 MG Extended Release Oral Capsule [Pentasa]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is mesalamine 500 MG Extended Release Oral Capsule [Pentasa] covered by Medicare Part D?
Yes, mesalamine 500 MG Extended Release Oral Capsule [Pentasa] is covered by 896 Medicare Part D plans (17.7% of all Part D formularies).
What tier is mesalamine 500 MG Extended Release Oral Capsule [Pentasa] on Medicare Part D plans?
mesalamine 500 MG Extended Release Oral Capsule [Pentasa] averages Tier 3.4 across Part D plans, ranging from Tier 1 to Tier 4.
Does mesalamine 500 MG Extended Release Oral Capsule [Pentasa] require prior authorization?
0% of Part D formularies require prior authorization for mesalamine 500 MG Extended Release Oral Capsule [Pentasa]. Step therapy: 0%. Quantity limits: 62.5%.
How much does Medicare spend on mesalamine 500 MG Extended Release Oral Capsule [Pentasa]?
In 2023, total Medicare Part D spending on mesalamine 500 MG Extended Release Oral Capsule [Pentasa] was $271,494,414, covering 95,185 beneficiaries. The average spend per beneficiary was $2,852.28.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- midazolam 50 MG/ML Nasal Spray [Nayzilam] T3.4
- phenytoin sodium 100 MG Extended Release Oral Capsule [Dilantin] T3.4
- leuprolide acetate 22.5 MG Injection T3.4
- 1.7 ML denosumab-qbde 70 MG/ML Injection [Xtrenbo] T3.4
- 3 ML insulin aspart-szjj 100 UNT/ML Pen Injector [Merilog] T3.4
- insulin aspart-szjj 100 UNT/ML Injectable Solution [Merilog] T3.4